Cargando…
Azathioprine immunosuppression and disease modification in Parkinson’s disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol
INTRODUCTION: The immune system is implicated in the aetiology and progression of Parkinson’s disease (PD). Inflammation and immune activation occur both in the brain and in the periphery, and a proinflammatory cytokine profile is associated with more rapid clinical progression. Furthermore, the ris...
Autores principales: | Greenland, Julia C, Cutting, Emma, Kadyan, Sonakshi, Bond, Simon, Chhabra, Anita, Williams-Gray, Caroline H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7684836/ https://www.ncbi.nlm.nih.gov/pubmed/33234645 http://dx.doi.org/10.1136/bmjopen-2020-040527 |
Ejemplares similares
-
Case Report: Azathioprine: An Old and Wronged Immunosuppressant
por: Chocair, Pedro R., et al.
Publicado: (2022) -
Thalidomide Combined With Azathioprine as Induction and Maintenance Therapy for Azathioprine-Refractory Crohn's Disease Patients
por: Li, Tong, et al.
Publicado: (2020) -
The influence of serial 50 μL microsampling on rats administered azathioprine, the immunosuppressive drug
por: Tanaka, Yoichi, et al.
Publicado: (2023) -
Refractory Celiac Disease Successfully Treated With Azathioprine
por: Iqbal, Umair, et al.
Publicado: (2017) -
Hailey-Hailey disease: the role of azathioprine an immunomodulator
por: Malan, Malumani, et al.
Publicado: (2019)